Kinase inhibitors in cancer therapy: a look ahead
- PMID: 10776829
- DOI: 10.2165/00003495-200059030-00004
Kinase inhibitors in cancer therapy: a look ahead
Abstract
The most essential kinases involved in cell membrane receptor activation, signal transduction and cell cycle control or programmed cell death and their interconnections are reviewed. In tumours, the genes of many of those kinases are mutated or amplified or the proteins are overexpressed. The use of key kinases offers the possibility to screen in vitro for synthetic small molecule kinase inhibitors. In view of the many interconnections of cellular kinases, their role in preventing or inducing programmed cell death and the possibility that a considerable number of signal transducing proteins are still unknown, cellular test systems are recommended in which the respective key kinase or one of its main partner molecules are overexpressed.
Similar articles
-
Alterations in the growth factor signal transduction pathways and modulators of the cell cycle in endocervical cells from macaques exposed to TCDD.Toxicol Appl Pharmacol. 1998 Aug;151(2):283-93. doi: 10.1006/taap.1998.8470. Toxicol Appl Pharmacol. 1998. PMID: 9707505
-
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005. Semin Oncol. 2006. PMID: 16890796 Review.
-
Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells.Endocrinology. 2004 Nov;145(11):4976-84. doi: 10.1210/en.2004-0713. Epub 2004 Jul 22. Endocrinology. 2004. PMID: 15271882
-
[ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].Klin Onkol. 2010;23(4):203-9. Klin Onkol. 2010. PMID: 20806817 Review. Czech.
-
Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk.Mol Cell Biol. 2005 May;25(9):3831-41. doi: 10.1128/MCB.25.9.3831-3841.2005. Mol Cell Biol. 2005. PMID: 15831486 Free PMC article.
Cited by
-
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?World J Clin Oncol. 2011 Feb 10;2(2):80-93. doi: 10.5306/wjco.v2.i2.80. World J Clin Oncol. 2011. PMID: 21603317 Free PMC article.
-
Discovery of nontriterpenoids from the rot roots of Panax notoginseng with cytotoxicity and their molecular docking study and experimental validation.RSC Adv. 2023 Apr 6;13(16):11037-11043. doi: 10.1039/d3ra00720k. eCollection 2023 Apr 3. RSC Adv. 2023. PMID: 37033442 Free PMC article.
-
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.BMC Cancer. 2006 May 18;6:133. doi: 10.1186/1471-2407-6-133. BMC Cancer. 2006. PMID: 16709245 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Clin Pharmacokinet. 2011 Sep;50(9):551-603. doi: 10.2165/11593320-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21827214
-
Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.J Enzyme Inhib Med Chem. 2019 Dec;34(1):532-546. doi: 10.1080/14756366.2018.1564046. J Enzyme Inhib Med Chem. 2019. PMID: 30688116 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
